Bridging the gaps in 18F PET tracer development

Campbell, Michael G.; Mercier, Joel; Genicot, Christophe; Gouverneur, Véronique; Hooker, Jacob M.; Ritter, Tobias

doi:10.1038/nchem.2693

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Bridging the gaps in ¹⁸F PET tracer development

MPS-Authors

/persons/resource/persons198096

Ritter, Tobias
Department of Chemistry and Chemical Biology, Harvard University;
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital;
Research Department Ritter, Max-Planck-Institut für Kohlenforschung, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Campbell, M. G., Mercier, J., Genicot, C., Gouverneur, V., Hooker, J. M., & Ritter, T. (2017). Bridging the gaps in ¹⁸F PET tracer development. Nature Chemistry, 9(1), 1-3. doi:10.1038/nchem.2693.

Cite as: https://hdl.handle.net/21.11116/0000-0000-D565-E

Abstract

As compared to the drug discovery process, the development of new ¹⁸F PET tracers lacks a well-established pipeline that advances compounds from academic research to candidacy for (pre)clinical imaging. In order to bridge the gaps between methodological advances and clinical success, we must rethink the development process from training to implementation.